Loading...
•
Dec 31, 2020
ResMed Q2 2021 Earnings Report
ResMed's second-quarter results reflected continued solid performance with top-line growth and double-digit improvement in operating income and earnings per share.
Key Takeaways
ResMed Inc. reported a 9% increase in revenue to $800.0 million for the second quarter of fiscal year 2021. GAAP diluted earnings per share were $1.23, and non-GAAP diluted earnings per share were $1.41. The company saw growth in its core markets and adoption of digital health solutions.
Revenue increased by 9% year-over-year to $800.0 million.
GAAP gross margin was 57.8%, while non-GAAP gross margin expanded to 59.9%.
Net operating profit increased by 12%, and non-GAAP operating profit rose by 16%.
GAAP diluted earnings per share reached $1.23, and non-GAAP diluted earnings per share were $1.41.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Revenue by Segment
Total Devices Revenue
CapyFin.comTotal Masks and other Revenue
CapyFin.comResidential Care Software Revenue
CapyFin.comRevenue by Geographic Location
U.S., Canada, and Latin America Revenue
CapyFin.comEurope, Asia, and other markets Revenue
CapyFin.com Forward Guidance
No specific forward guidance was provided in the release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income